But efficacy in NSCLC has slipped since the abstract, and a high rate of rash raises eyebrows.

Phase 1 data suggest the group’s KRAS G12C inhibitor has activity, crucially in KRAS-experienced patients. 

But Repare and Black Diamond still have rebuilding to do.

Mirati raises $300m as its chief exec departs. What’s not to like?